CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
March 21, 2024—Bayer and Thermo Fisher Scientific announced that they will develop next-generation sequencing–based companion diagnostic assays to help identify patients who may benefit from Bayer’s precision cancer therapies. The assays will be developed using Thermo Fisher’s Oncomine Dx Express test on the Ion Torrent Genexus Dx system.
“We are committed to providing simple and fast next-generation sequencing–based solutions using tumor and liquid biopsy samples that support future access to targeted therapies, thereby helping to improve patient outcomes,” Garret Hampton, president of clinical NGS and oncology at Thermo Fisher Scientific, said in a press statement. “The combination of our experience in developing distributable CDx tests with the game-changing turnaround time offered by our Genexus Dx system allows clinical teams to quickly gather results to better understand the impact of these therapies. Pairing this with Bayer’s growing precision oncology portfolio, we are well positioned for the potential to help ensure that eligible patients can be quickly matched with the right treatment.”